ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Acadia Pharma (ACAD) Tops Q2 EPS by 17c
August 5, 2020 4:57 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.27), $0.17 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $110 million versus the consensus estimate of $103.34 million.
At June 30, 2020, ACADIAs cash, cash equivalents, and investment securities totaled $658.6 million, compared to $697.4 million at December... More
